FDA Rejects MDMA-Based PTSD Treatment Proposal

The U.S. FDA has declined to approve an MDMA-based therapy for treating PTSD, as the data submitted by developer Lykos Therapeutics was deemed insufficient. Despite the drug's potential therapeutic applications, it remains a common illicit substance, known as ecstasy or molly.

The U.S. Food and Drug Administration (FDA) has declined to approve the first-ever MDMA-based treatment for post-traumatic stress disorder (PTSD). The decision was announced by developer Lykos Therapeutics on Friday, citing insufficient data submitted for approval.

MDMA, commonly known as ecstasy or molly, has garnered attention from mental health advocates for its potential to treat various mental health disorders. Proponents argue that the drug's therapeutic benefits outweigh its negative connotations as a recreational substance.

However, the FDA's decision highlights the ongoing scrutiny and rigorous standards applied to ensure patient safety and effective treatment outcomes.

(With inputs from agencies.)